News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

BIO Statement on Passage of the Reconciliation…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on passage of the One, Big, Beautiful Bill Act (OBBBA):“The OBBBA contains important bipartisan provisions…

Learn more

Massachusetts Governor Maura Healey Named BIO’s…

Annual award honors governors for their leadership and commitment to strengthening biotechnology in their state BOSTON (June 17, 2025) – Today, the Biotechnology Innovation Organization (BIO) named Massachusetts Governor Maura Healey…

Learn more

BIO Elects Genentech’s Fritz Bittenbender as New…

Industry veteran takes the helm as Dr. Ted Love concludes two-year term marked by strategic growth and transition BOSTON (June 16, 2025) – Today, the Biotechnology Innovation Organization (BIO) announced that Fritz Bittenbender,…

Learn more

Letters, Testimony, & Comments

Browse All

CSBA Letter to Congressional Leadership…

Learn more

John F. Crowley, President and CEO of the…

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s…

Learn more

CSBA Letter to Congressional Leadership on Most…

Learn more

Amicus Briefs

Browse All

BIO Files Amicus Brief in Delaware Supreme Court…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …

Learn more

BIO Files Amicus Briefs Supporting the Lawfulness…

On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…

Learn more

BIO Files Amicus Brief on FDA Orange Book Listing…

BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit urging rehearing of a case involving whether certain Teva Pharmaceuticals patents had been properly listed in FDA’s Orange Book (Approved Drug Products with Therapeutic…

Learn more